| Schedule of antidilutive due to the loss incurred for the periods |
|
|
|
|
|
|
|
|
| |
|
December 31,
2025 |
|
|
December 31,
2024 |
|
| Numerator: |
|
|
|
|
|
|
|
|
| Net loss available to common shareholders |
|
₣ |
(66,613,990 |
) |
|
₣ |
(28,132,971 |
) |
| |
|
|
|
|
|
|
|
|
| Denominator: |
|
|
|
|
|
|
|
|
| Weighted-average common shares outstanding used in computing loss per share available to common stockholders, basic and diluted |
|
|
14,474,974 |
|
|
|
14,051,547 |
|
| Basic and diluted net loss per share |
|
₣ |
(4.60 |
) |
|
₣ |
(2.00 |
) |